Drug Profile
MV 6401
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Miravant Medical Technologies
- Class
- Mechanism of Action Photosensitisers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Coronary artery restenosis; Solid tumours; Vascular restenosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Coronary-artery-restenosis in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Vascular-restenosis in USA